Search

Your search keyword '"Westenbrink, Berend Daan"' showing total 4 results
Start Over Author "Westenbrink, Berend Daan" Database OAIster
4 results on '"Westenbrink, Berend Daan"'

1. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Author

de Brouwer, Remco, te Rijdt, Wouter P., Hoorntje, Edgar T., Amin, Ahmad, Asselbergs, Folkert W., Cox, Moniek G.P.J., van der Heijden, Jeroen F., Hillege, Hans, Karper, Jacco C., Mahmoud, Belend, van der Meer, Peter, Oomen, Anton, te Riele, Anneline S.J.M., Silljé, Herman H.W., Tan, Hanno L., van Tintelen, Jan Peter, van Veldhuisen, Dirk J., Westenbrink, Berend Daan, Wiesfeld, Ans C.P., Willems, Tineke P., van der Zwaag, Paul A., Wilde, Arthur A.M., de Boer, Rudolf A., van den Berg, Maarten P., de Brouwer, Remco, te Rijdt, Wouter P., Hoorntje, Edgar T., Amin, Ahmad, Asselbergs, Folkert W., Cox, Moniek G.P.J., van der Heijden, Jeroen F., Hillege, Hans, Karper, Jacco C., Mahmoud, Belend, van der Meer, Peter, Oomen, Anton, te Riele, Anneline S.J.M., Silljé, Herman H.W., Tan, Hanno L., van Tintelen, Jan Peter, van Veldhuisen, Dirk J., Westenbrink, Berend Daan, Wiesfeld, Ans C.P., Willems, Tineke P., van der Zwaag, Paul A., Wilde, Arthur A.M., de Boer, Rudolf A., and van den Berg, Maarten P.

Abstract

Phospholamban (PLN; p.Arg14del) cardiomyopathy is an inherited disease caused by the pathogenic p.Arg14del variant in the PLN gene. Clinically, it is characterized by malignant ventricular arrhythmias and progressive heart failure.1,2 Cardiac fibrotic tissue remodelling occurs early on in PLN p.Arg14del carriers.3,4 Eplerenone was deemed a treatment candidate because of its beneficial effects on ventricular remodelling and antifibrotic properties.5,6 We conducted the multicentre randomized trial ‘intervention in PHOspholamban RElated CArdiomyopathy STudy’ (i-PHORECAST) to assess whether treatment with eplerenone of asymptomatic PLN p.Arg14del carriers attenuates disease onset and progression.

Published
2023

2. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Author

Cardiologie, Team Medisch, Team Onderzoek, Circulatory Health, Onderzoek Device, Genetica, Genetica Groep Van Tintelen, Child Health, de Brouwer, Remco, te Rijdt, Wouter P., Hoorntje, Edgar T., Amin, Ahmad, Asselbergs, Folkert W., Cox, Moniek G.P.J., van der Heijden, Jeroen F., Hillege, Hans, Karper, Jacco C., Mahmoud, Belend, van der Meer, Peter, Oomen, Anton, te Riele, Anneline S.J.M., Silljé, Herman H.W., Tan, Hanno L., van Tintelen, Jan Peter, van Veldhuisen, Dirk J., Westenbrink, Berend Daan, Wiesfeld, Ans C.P., Willems, Tineke P., van der Zwaag, Paul A., Wilde, Arthur A.M., de Boer, Rudolf A., van den Berg, Maarten P., Cardiologie, Team Medisch, Team Onderzoek, Circulatory Health, Onderzoek Device, Genetica, Genetica Groep Van Tintelen, Child Health, de Brouwer, Remco, te Rijdt, Wouter P., Hoorntje, Edgar T., Amin, Ahmad, Asselbergs, Folkert W., Cox, Moniek G.P.J., van der Heijden, Jeroen F., Hillege, Hans, Karper, Jacco C., Mahmoud, Belend, van der Meer, Peter, Oomen, Anton, te Riele, Anneline S.J.M., Silljé, Herman H.W., Tan, Hanno L., van Tintelen, Jan Peter, van Veldhuisen, Dirk J., Westenbrink, Berend Daan, Wiesfeld, Ans C.P., Willems, Tineke P., van der Zwaag, Paul A., Wilde, Arthur A.M., de Boer, Rudolf A., and van den Berg, Maarten P.

Published
2023

3. Erythropoietin in heart failure:Pathology and protection

Author

Westenbrink, Berend Daan, Westenbrink, Berend Daan, Westenbrink, Berend Daan, and Westenbrink, Berend Daan

Abstract

Anemia is common in chronic heart failure (CHF) patients and related to impaired survival. The etiology of anemia in CHF-patients is often unknown. We hypothesized that dysregulation of erythropoietin (EPO) synthesis by the kidney or an altered sensitivity of the bone marrow to EPO might represent causes specific for CHF. In addition, recombinant human EPO (rhEPO) has been shown to improve cardiac function in heart failure. We hypothesized that EPO-induced improvement of cardiac function is mediated through mechanisms that are unrelated to increases in hematocrit levels. In the present thesis we explored EPO as a pahthophysiological factor in anemia and the mechanisms of its ancillary beneficial cardiac effects in heart failure.

Published
2008

4. Erythropoietin in heart failure:Pathology and protection

Author

Westenbrink, Berend Daan and Westenbrink, Berend Daan

Abstract

Anemia is common in chronic heart failure (CHF) patients and related to impaired survival. The etiology of anemia in CHF-patients is often unknown. We hypothesized that dysregulation of erythropoietin (EPO) synthesis by the kidney or an altered sensitivity of the bone marrow to EPO might represent causes specific for CHF. In addition, recombinant human EPO (rhEPO) has been shown to improve cardiac function in heart failure. We hypothesized that EPO-induced improvement of cardiac function is mediated through mechanisms that are unrelated to increases in hematocrit levels. In the present thesis we explored EPO as a pahthophysiological factor in anemia and the mechanisms of its ancillary beneficial cardiac effects in heart failure.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results